DAIC
JULY 18, 2024
HeartFlow’s Plaque Analysis uses proprietary algorithms to analyze coronary CT angiogram (CCTA) scans, creating a personalized 3D model that quantifies and characterizes plaque volume in the coronary arteries, aiding risk assessment of coronary artery disease. Narula et al.
DAIC
DECEMBER 5, 2024
Cleerly is dedicated to creating a new standard of care for heart disease by using FDA-cleared solutions powered by artificial intelligence. As we’ve seen with their recent Medicare and CPT I code approvals, this technology is both valuable and ready today in the fight against heart disease.”
Society of Thoracic Surgeons - Congenital
JANUARY 25, 2025
Hunter Mehaffey, MD, a cardiothoracic surgeon from West Virginia University, will examine results comparing two treatment options Transcatheter vs. Surgical Aortic Valve Replacement in Medicare Beneficiaries with Aortic Stenosis and Significant Coronary Disease.
DAIC
OCTOBER 15, 2024
15, 2024 – Elucid has announced that four of the seven Medicare Administrative Contractors (MACs) will extend coverage for AI-enabled quantitative coronary plaque analysis, including its FDA-cleared PlaqueIQ image analysis software, beginning Nov. tim.hodson Tue, 10/15/2024 - 12:12 Oct.
DAIC
OCTOBER 16, 2024
15 , 2024 — Four of the seven Medicare Administrative Contractors (MACs) have released final local coverage determinations (LCD) for AI-Coronary Plaque Analysis (AI-CPA). tim.hodson Wed, 10/16/2024 - 12:36 Oct. The four contractors for the U.S. The LCDs have a future effective date of Nov. 24, 2024.
DAIC
MAY 8, 2024
1 Atherosclerosis is a systemic disease that affects multiple vascular regions and is particularly severe in PAD patients, where up to 80 percent suffer from concurrent coronary artery disease (CAD), historically linked with a mortality rate exceeding 50 percent within five years. 301–302, [link]. 3 Secemsky, Eric A.,
DAIC
JUNE 18, 2024
The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary artery disease. The DynamX bioadaptor has a novel design and mechanism of action designed to return the diseased vessel to a more normal condition, through three distinct phases.
Expert insights. Personalized for you.
111 
Let's personalize your content